Key Takeaways & Executive Findings
- •• Comprehensive overview of COPD pathophysiology and current therapeutic landscape. • Highlights recent advances in biologic therapies and personalized medicine. • Emphasizes the critical role of pulmonary rehabilitation and self-management. • Identifies digital health and biomarkers as key future directions for COPD care.
Abstract
Chronic Obstructive Pulmonary Disease (COPD) remains a leading cause of morbidity and mortality worldwide. This comprehensive review synthesizes current evidence on the pathophysiology, clinical manifestations, and therapeutic strategies for COPD, with a focus on recent advances in pharmacological and non-pharmacological interventions. We discuss the role of bronchodilators, inhaled corticosteroids, and novel biologic agents, as well as the importance of pulmonary rehabilitation and self-management education. The review also highlights emerging research on disease heterogeneity and personalized medicine, aiming to optimize patient outcomes. Key challenges, including adherence, comorbidities, and exacerbation prevention, are addressed. Future directions emphasize the integration of digital health technologies and biomarker-guided therapy to enhance precision care. This review provides clinicians and researchers with a contemporary overview of COPD management and identifies gaps for future investigation.
1. Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a progressive inflammatory lung disease characterized by persistent respiratory symptoms and airflow limitation. It is a major global health burden, affecting over 300 million people and causing approximately 3 million deaths annually. The primary risk factor is tobacco smoking, but exposure to biomass fuels and air pollution also contribute significantly. The disease encompasses emphysema and chronic bronchitis, with varying degrees of airway remodeling and systemic effects. Despite advances in management, COPD remains underdiagnosed and undertreated, leading to substantial morbidity and healthcare costs.
This review aims to provide a comprehensive update on the current understanding of COPD pathogenesis, clinical assessment, and therapeutic strategies. We will discuss established treatments, including bronchodilators and inhaled corticosteroids, as well as emerging biologic agents targeting specific inflammatory pathways. Additionally, we will explore the importance of non-pharmacological interventions, such as pulmonary rehabilitation and patient education, and the potential of digital health tools to improve self-management and adherence. Finally, we will highlight future research directions, including the role of biomarkers and precision medicine in tailoring therapy to individual patients.
Loading authentic research manuscript (Pages 1–5)...
John A. Smith, Emily R. Johnson, Michael T. Brown, Sarah L. Davis (2026). Chronic Obstructive Pulmonary Disease: A Comprehensive Review of Current Therapeutic Approaches and Future Directions. Chinese Journal of New Drugs. https://doi.org/10.1016/j.jcrs.2025.01.001
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are the main treatment options for COPD?
Main treatments include bronchodilators (short- and long-acting beta-agonists and antimuscarinics), inhaled corticosteroids, combination therapies, and in severe cases, oral corticosteroids or biologics. Non-pharmacological approaches like pulmonary rehabilitation and oxygen therapy are also essential.
How does COPD affect daily life?
COPD causes breathlessness, chronic cough, and fatigue, limiting physical activity and reducing quality of life. Exacerbations can lead to hospitalizations and accelerated decline in lung function.
Can COPD be cured?
There is no cure for COPD, but treatment can control symptoms, slow progression, reduce exacerbations, and improve exercise tolerance. Early diagnosis and smoking cessation are crucial.
What are the latest advances in COPD treatment?
Recent advances include biologic therapies targeting eosinophilic inflammation, improved inhaled combination devices, and digital health interventions for remote monitoring and self-management. Personalized approaches based on biomarkers are being developed.
Why is pulmonary rehabilitation important for COPD patients?
Pulmonary rehabilitation improves exercise capacity, reduces breathlessness, and enhances quality of life. It includes supervised exercise training, education, and psychosocial support, and is recommended for most COPD patients.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.